

CURRICULUM VITAE

Joachim Raese, MD

LICENSES

CA Medical License No. A33990
DEA Registration No. FR0151251

CERTIFICATIONS

American Board of Psychiatry & Neurology, Diplomate
1992-present

CURRENT POSITION

Chair Department of Psychiatry
Psychiatric Medical Director
Associate Residency Training Director and Academic Chair
Adjunct Professor of Clinical Medicine
University of California-Irvine Affiliate
Kaweah Delta Health Care District
1100 S. Akers Street
Visalia, CA 93277

Current Employment

Traditions Behavioral Health
Psychiatric Medical Director
Associate Residency Training Director

Current Professional Staff Privileges

Kaweah Delta Health Care District

Current Clinical Practice Position

Psychiatrist
Kaweah Delta Mental Health Hospital
1100 S. Akers Street
Visalia, CA 93277

Current Academic Positions

Adjunct Professor of Clinical Medicine

RESEARCH EXPERIENCE

Clinical Trials

CHILD & ADOLESCENT CLINICAL TRIAL

Principal Investigator, "A Twelve Week, Randomized, Double- Blind, Double-Dummy, Placebo- and Active- Controlled Study of Drug® and Drug Administered Once Daily in Adults and Adolescents with Asthma"

Principal Investigator, "A Double- Blind, Placebo-Controlled, 4- Week Study of the Safety and Efficacy of Drug in Children and Adolescents with Acute Manic or Mixed Episodes of Bipolar Disorder, with an Optional 6- Month Open-Label Extension"

Principal Investigator, " A 6-week, International, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Drug – Drug Immediate-release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia"

Principal Investigator, "A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active -Controlled Study of Drug and Drug Administered Once Daily in Adults and Adolescents with Asthma"

Principal Investigator, "A 3-Week, Multicenter, Randomized, Double-Blind, Parallel group, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Drug Immediate-Release Tablets in Daily Doses of 400 Mg and 600 Mg Compared with Placebo in the Treatment of Children and Adolescent with Bipolar I Mania"

Principal Investigator, "A Double-Blind, Placebo-Controlled, 4-Week Study of the Safety and Efficacy of Drug in Children and Adolescents with Acute Manic or Mixed Episodes of bipolar Disorder, with an Optional 6-Month Open-Label Extension"

Principal Investigator, "A Double-Blind Flexible Dose of Drug in Pediatric Patients with Major Depressive Disorder"

Principal Investigator, "An Open-Label Extension Study of the Safety and Efficacy of Drug in Pediatric Patients with Major Depressive Disorder"

Principal Investigator, "The Efficacy and Safety of Drug in the Treatment of Adolescents with Schizophrenia: Extension Trial"

Principal Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Drug 10 Mg or 30 Mg in the Treatment of Adolescents Patients with Schizophrenia"

Principal Investigator, "A 6-Week, International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Drug Immediate-Release Tablets in Daily Doses of 400 Mg and 800 Mg Compared with Placebo in the Treatment of Adolescent with

Schizophrenia"

Principal Investigator," The Efficacy and Safety of Drug in the Treatment of Adolescent with Schizophrenia"

Principal Investigator, "A Multicenter, Open Label, Safety and Tolerability Study of Flexible-Dose Oral Drug 2 Mg-30 Mg in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode"

Principal Investigator, " A 26-Week, International, Multicenter, Open-Label Phase IIIb Study of the Safety and Tolerability of Drug Immediate-Release Tablets in Daily Doses of 400Mg to 800 Mg in Children and Adolescent with Bipolar I Disorder and Adolescent with Schizophrenia"

"Drug for the Treatment of Tardive Dyskinesia in Schizophrenic Daily Doses of 400 Mg to 800 Mg in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia"

"A Double-Blind, Randomized, Placebo Controlled Study of Drug in Adolescent Patients with Bipolar Disorder"

Principal Investigator, "A 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Drug in Children and Adolescents Ages 9 to 17 Years With Insomnia"

Principal Investigator, "A Double-Blind, Randomized Comparison of the Safety and Efficacy of Drug and Drug in the Treatment of Adolescents in the Manic Phase of Bipolar Disorder"

Principal Investigator, "A Double-Blind, Randomized Comparison of the Safety and Efficacy of Drug and Drug in the Treatment of Children and Adolescents, Ages 7 to 17 Years, in the Treatment of the Manic Phase of Bipolar Disorder"

Principal Investigator, " A Double-Blind, Placebo-Controlled, 4-Week Study of the Safety and Efficacy of Drug in Children and Adolescents with Acute Manic or Mixed Episodes of Bipolar Disorder, with an Optional 6-Month Open-Label Extension"

**ADULT CLINICAL
TRIAL EXPERIENCE**

Principal Investigator, "An Evaluation of the Efficacy and Safety of Drug CR in the Treatment of the Manic Phase of Bipolar Disorder: a Placebo- Controlled Study"

Principal Investigator, A Double- Blind, Randomized Comparison of the

Safety and Efficacy of Drug and Drug (Drug) in Treatment Resistant Schizophrenic Patients"

Principal Investigator, "A Double- Blind, Randomized Comparison of the Safety and Efficacy of Drug and Drug in Treatment Resistant Schizophrenia Patients"

A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of Drug -Drug (oral tablets 400 mg to 800 mg daily in divided doses) to placebo When Used as Adjunct to Mood Stabilizers (Drug or Drug) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

Principal Investigator, "A Multicenter, Double- Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Drug as Add-on Therapy with Drug or Drug in the Treatment of Acute Mania"

Principal Investigator, "A Double- Blind, Placebo- Controlled Study of the Safety and Efficacy of Drug Compared to Drug in Patient with Major Depressive Disorder"

Principal Investigator, "A multicenter, Randomized, Double-Blind, Placebo Controlled Study of Drug Monotherapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder

Principal Investigator, "A Randomized, Double-Blind Comparison of the Efficacy and Safety of Drug Intramuscular Formula, Drug, or Placebo in the Treatment of Acutely Agitate Patients Diagnosed with Bipolar I Disorder, Manic or Mixed “

Principal Investigator, "A Randomized, Double-Blind Comparison of the Efficacy and Safety of Drug Intramuscular Formula, Drug, or Placebo in the Treatment of Acutely Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective Disorder

Principal Investigator, "A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study of Drug in the Maintenance Treatment of Patients with Bipolar Disorder"

Principal Investigator, "A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study of Drug in the Treatment of Acutely Manic Patients with Bipolar Disorder"

Principal Investigator, "A Multicenter, Randomized, Double- Blind, Study of Drug versus Placebo in the Treatment of Acutely Manic Patients with Bipolar Disorder"

Principal Investigator, "A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study of Two Fixed Doses of Drug in the Treatment of Hospitalized Patients with Acute Mania"

Principal Investigator, "A Multicenter, Randomized, Double- Blind, Placebo-Controlled Study of Flexible Doses of Drug in the Treatment of Hospitalized Patients with Acute Mania"

Principal Investigator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Doses of Drug in the Treatment of Hospitalized Patients with Acute Mania"

Principal Investigator, "Double- Blind Comparison of Drug, Drug and Placebo in Schizophrenia Patients"

Principal Investigator, "A Multicenter, Double- Blind Comparison of Drug, Drug, Drug and Placebo in Schizophrenic Patients"

Principal Investigator, "A Double- Blind, Dose- Ranging Trial Comparing Drug to Placebo to Drug in Hospitalized Patients with Acute Exacerbation of Chronic Schizophrenia"

Principal Investigator," A Phase III Pivotal, Multi-center, Double-Blind, Randomized, Placebo-controlled Mono-therapy Study of Drug for Treatment of Fibromyalgia "

Principal Investigator, "Bipolar Disorder Effectiveness Study"(BIDES)

Principal Investigator, "Placebo- Controlled Drug Monotherapy in the Treatment of Bipolar I Depression"

Principal Investigator, "Drug versus Placebo in the Prevention of Relapse in Bipolar Disorder"

Principal Investigator, "Drug for the Treatment of Tardive Dyskinesia in Schizophrenic Patients"

Principal Investigator, "An Open- Label Study Assessing Drug CR in Subjects with Major Depressive Disorder who Discontinued Treatment with Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/ Norepinephrine Reuptake Inhibitor"

Principal Investigator, "A Double- Blind Comparison of Drug versus Drug-Drug

in Schizophrenic Patient"

Principal Investigator, "A double-blind, randomized, prospective trial to evaluate augmentation of Drug with Drug versus placebo in patients with Major Depressive Disorder refractory to Drug and prior antidepressant "

Principal Investigator, "A double-blind, randomized, prospective, eight-week, study to evaluate adjunctive risperidone versus adjunctive placebo in Generalized Anxiety Disorder sub-optimally responsive to standard psychotropic therapy "

Principal Investigator, "A Double- Blind, Multicenter, Placebo- Controlled Study of Drug-Drug Gel Extrusion Module (GEM) 1.5 mg B.I.D. to 4.5 mg B.I.D. in the Treatment of Outpatients with Generalized Anxiety Disorder"

Principal Investigator, "Drug (Drug-Drug) Versus Placebo in the Treatment of Major Depressive Disorder Resistant to Drug"

Principal Investigator, "A Phase III, Randomized, Placebo- Controlled, Double-Dummy Study Evaluating the Safety and Efficacy of Oral Drug vs. Drug and Placebo in Patients with an Acute Manic Episode"

Principal Investigator, "An International, Multicenter Large Simple Trial (LST) to Compare the Cardiovascular Safety of Drug and Drug"

Principal Investigator, "A 52- Week (1 Year) Open Extension Study Evaluation of the Safety and Efficacy of Continued Administration of 40-160mg Daily of Oral Drug in the Treatment of Subjects Who Have Participated in Previous Drug Clinical Trials"

Principal Investigator, "A Double- Blind, Multicenter, Controlled Study Comparing the Safety and Efficacy of Drug and Drug to Placebo with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care"

Principal Investigator, "A Double- Blind Six- Month Continuation Protocol for Patients Who Successfully Completed Protocol # Drug-Drug"

Principal Investigator, "DNA/ RNA/ SERUM Banking in Subjects with Early Onset Alzheimer's disease"

Principal Investigator, "DNA/ RNA/ SERUM Banking in Subjects with Late Onset Alzheimer's Disease"

Principal Investigator, "A Randomized, Prospective, Double- Blind, Placebo-

Controlled, Multi- Stage, Dose- Finding Study of Drug in DSM-111-R Defined Institutionalized Schizophrenic Patients"

Principal Investigator, "A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Fixed- Dose, Multicenter Study of Weight Reducing Effect and Safety of Drug in Obese Patients with or without Comorbidities"

Principal Investigator, "Depression Response to Drug in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, 8-Week, Safety and Efficacy Study of Drug 3 mg Compared to Placebo in Subjects with Insomnia related to Major Depressive Disorder "

Principal Investigator, "A Phase III Safety Study to Evaluate the Long- Term Effects of Drug- Drug on Endocrine Function in Adult Subjects with Chronic Insomnia"

Principal Investigator, "A Phase II Randomized, Multicenter, Placebo-Active- Controlled Study of Oral Drug-Drug in Subjects with Major Depressive Disorder"

Principal Investigator, "A Double- Blind Inpatient Study of Drug Versus Drug and Placebo for Schizophrenia"

Principal Investigator, "A 21-Day, Double- Blind, Placebo- Controlled, Parallel- Group Evaluation of the Efficacy and Safety of Drug in the Treatment of the Manic Phase of Bipolar Disorder"

SPECIAL AWARDS

Department of Veteran Affairs Career Development Award,
Clinical Investigator
1984 – 1990

Fellowship Award, National Institutes of Health (NIH),
Neurobiology & Molecular Biology
1982

Fellowship Award, German Society for Advancement of Science,
Postdoctoral Training in USA
1974

JOACHIM RAESE, MD

CV PAGE 8

**PROFESSIONAL
POSITIONS**

Medical Director Kaweah Mental Health Hospital
Associate Residency Training Director and Academic Chair
Traditions Behavioral Health
2010 – present

Senior Psychiatrist
Napa State Hospital
2100 Napa Vallejo Highway
Napa, CA 94558
2008 – 2010

NeuroNetwork Trials
12/2007 – 7/2008
Co-founder and Medical Director

Pacific Clinical Research Medical Group
2006 – 2007
Principal Investigator

Behavioral Health 2000, LLC
2001 – 2006
Medical Director and Founder

Dr. Raese and Associates
1995 – 2006
Medical Director and Founder

**PROFESSIONAL
AFFILIATIONS**

Charter Behavioral Health Systems of Southern California
Corona, CA 92879
Medical Director
1990 – 1996

Dallas Veteran's Administration Medical Center Dallas, TX 75216
Medical Director, Schizophrenia Research Center
1985 – 1990

Dallas Veteran's Administration Medical Center Dallas, TX 75216
Medical Director, SPECIAL DIAGNOSTIC AND TREATMENT UNIT
1982 – 1990

EDUCATION

Hamburg University, School of Medicine
Hamburg, Germany
Medical Degree

1967 – 1971

University of Hamburg
Hamburg, Germany
Bachelor of Science
1964 – 1967

INTERNSHIPS

Stanford Hospital, Stanford University Medical Center
401 Quarry Road
Stanford, CA 94305
Internship, Psychiatry
1979 – 1979

Santa Clara Medical Center
Santa Clara, CA 95051
Internship, Psychiatry
1978 – 1979

Humboldt Hospital
Berlin, Germany
Internship, Psychiatry
1971 – 1972

RESIDENCY

Stanford University, School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Residency in Psychiatry
1981 – 1982

Stanford University, Stanford University Clinic
300 Pasteur Drive
Stanford, CA 94305
Residency in Psychiatry
1980 – 1980

Veteran's Administration Medical Center
3801 Miranda Avenue
Palo Alto, CA 94304
Residency in Psychiatry
1979 – 1981

PUBLICATIONS

Lui K, Randhawa G, Smith A, Totten V, Raese J (2015) Is Metabolic Syndrome

on the Radar? Improving the real time detection of Metabolic Syndrome and physician-response by computerized scan of the Electronic Medical Record

Submitted to J Clin Psychiatry

Psychosis and Capgras delusions in a patient diagnosed with Cogan's syndrome.
Raese J, Fayaz Ibrahim F (2015) *in press*

Raese J (2014) The Pernicious Effects of Mind/Body Dualism in Psychiatry.
<http://dx.doi.org/10.4172/1994-8220.1000219>

Human Dystonia Gene Found on Chromosome 9q32-q34", (L. Ozelius; P.L. Kramer; C.B. Moskowitz; D.J. Kwiatkowski; M.F. Brin; S.B. Bressman; D.E. J. D. Raese; J.F. Guzulla; S. Fahn; X.O. Bleakefield), American Society of Human Genetics, 1998

"Cerebellar Blood Flow in Schizophrenic Patients and Normal Control Subjects", (J.L. Steinberg; Devous, M.D; F.G. Moeller; R.G. Paulman; J.D. Raese; R.R. Gregory), Psychiatry Research: Neuroimaging, Volume 61, Issue 1, pp 15-31, 1995

"Serum Homovanillic Acid in Schizophrenic Patients and Normal Control Subjects", (J.L. Steinberg; D.L. Garver; F.G. Moeller; J.D. Raese; P.J. Orsulak), Psychiatric Research, Volume 48, pg 48, 93-106, 1993

"Effects of Tricyclic Antidepressant Treatment on Tyramine-Sulfate Excretion in Depressed Patients", (J.L. Steinberg; P.J. Orsulak; J.D. Raese; R.R. Gregory; M.H. Zielinski; P.D. Wittman), Journal of Affective Disorders, Volume 27, pp 29-34, 1993

"Heat Shock Protein Induction by Herpes Simplex Virus Type I in Human Embryonic Lung Cells", (P.A. Mackoik; M.L. Goggins; J. D. Raese; M.R. Morrison- Bogorad), Journal of Therm Biology, Volume 17, Chapter 1, pp 11-18, 1992

"Neurobiological Bases for Psychiatric Disorders", (J.A. Rush; J.W. Cain; J.D. Raese; R.S. Stewart; D.A. Waller; J.R. Debus), (ed.):
Rosenberg, RN; The Clinical Neurosciences, Raven Press, New York, NY, 2nd Edition, Volume 1, pp 555-603, 1991

"Expression of Heat Shock Protein 70 and Heat Shock Cognate 70 Messenger RNAs in Rat Cortex and Cerebellum After Heat Shock of Amphetamine Treatment", (E.K. Miller; J. D. Raese; M.R. Morrison- Bogorad), Journal of Neurochemistry, Volume 56, Issue 6, pp 2060-2071, 1991

“Differential Expression of Members of the Heat Shock Gene Family in Brain of Adult and Aged Rats”, *Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies* (K. Groshan; S. Pardue; B. Border; E.K. Miller; M.R. Morrison- Bogorad; J.D. Raese), Volume 29, pp 243-253, 1991

“Regional Cerebral Function and Blood Flow; Complimentary Single Photon Emission Computed Tomography of the Brain Using Xenon-133 and Iodine-123 Iodoamphetamine”, (T.R. Simon; M.D. Devous Sr.; R.G. Paulman; R.R. Gregory; R.W. Homan; C.R. Judd; J.G. Triebel; s. Mattiesen; J.D. Raese; F.J. Bonte), *Nuclear Medicine and Biology*, Volume 16, pp 295-300, 1989

“Hypofrontality and Cognitive Impairment in Schizophrenia”, (R.G. Paulman; M.D. Devous Sr.; R.R. Gregory; J.H. Herman; L. Jennings; F. J. Fonte; H.A. Nasrallah; J.D. Raese), *Biological Psychiatry*, Volume 27, (4), pp 377-399, 1989

“RFLP for Human DBH Gene”, (D.E. Schuback; L. Ozelius; G. Hu; C.M. Craft; J.D. Raese; X. O. Bleakefield; Y.P.P. Hsu), *Nuclear Acid Research*, Volume 18, (4), pp 2, 1989

“Neuropsychological Function in Positive and Negative Schizophrenia”, (M.J. Deschner; R.G. Paulman; C.R. Judd; A. Rubenstein; J. Hon; J.L. Steinberg; R.R. Gregory; J.D. Raese), *The Clinical Neuropsychologist*, Volume 3, Number 3, 1988

“Brain Electrical Activity Mapping in Paranoid Schizophrenia and Related Disorders”, (K.D. Pool; T. Finitzo; R.G. Paulman; C.R. Judd; R.R. Gregory; J.D. Raese), *Journal of Clinical and Experimental Neuropsychology*, Volume 10 (3), pgs 322, 1988

“Tyrosine Hydroxylase Immunocytochemistry and Quantitative Light Microscopic Studies of the Meso- Limbic Dopamine System in Rat Brain: Effects of Chronic Methamphetamine Administration”, (M.E. Trulson; M.S. Cannon; T.S. Faegg; J.D. Raese), *Brain Research Bulletin*, Volume 18, pgs 269-277, 1987

“Chronic Cocaine Administration Depletes Tyrosine Hydroxylase Immunoreactivity in the Meso- Limbic Dopamine System in Rat Brain: Quantitative Light Microscopic Studies”, (M.E. Trulson; J.C. Joe; S. Babb; J.D. Raese), *Brain Research Bulletin*, Volume 19, pgs 39-45, 1987

“A Human Gene Family with Sequence Homology to *Drosophila Melanogaster* Hsp 70 Heat Shock Genes”, (G.I. Mues; T.Z. Munn; J.D. Raese), *Journal of Biological Chemistry*, Volume 261 (2), pgs 874-877, 1986

“Chronic Cocaine Administration Depletes Tyrosine Hydroxylase Immunoreactivity in the Rat Brain Nigro- Striatal System: Quantitative Light Microscopic Studies”, (M.E. Trulson; S. Babb; J.C. Joe; J.D. Raese), Experimental Neurology, Volume 94, pgs 744-756, 1986

“Identification of Dopamine- Containing Cell Bodies in the Dorsal and Median Raphe Nuclei of the Rat Brain Using Tyrosine Hydroxylase Immunocytochemistry”, (M.E. Trulson; M.S. Cannon; J.D. Raese), Brain Research Bulletin, Volume 15, pgs 229-234, 1985

“Effects of Chronic Methamphetamine on the Nigro- Striatal Dopamine System in Rat Brain: Tyrosine Hydroxylase Immunocytochemistry and Quantitative Light Microscopic Studies”, (M.E. Trulson; M.S. Cannon; T.S. Faegg; J.D. Raese), Brain Research Bulletin, Volume 15, pgs 569-577, 1985

“Regional Cerebral Blood Flow in Schizophrenic Patients at Rest and During Wisconsin Card Sort Tasks”, (M.D. Devous Sr.; J.D. Raese; H.H. Herman; R.G. Paulman; R.R. Gregory; A. J. Rush, H.H. Chehabi, F.J. Bonte), Journal of Cerebral Flow Metabolism, Volume 5 (Supplemental 1), pgs S201-S202, 1985

“Neuropsychological Correlates of Regional Cerebral Blood Flow in Schizophrenia”, (R.G. Paulman; M.D. Devous Sr.; F.J. Bonte, H.H. Chehabi; R.R. Gregory; A.J. Rush; J.D. Raese), International Journal of Clinical Neuropsychology, Volume 7 (1), pg 58, 1985

“Regional Cerebral Blood Flow in Schizophrenic Patients at Rest and During Wisconsin Card Sort Tasks”, (J.H. Herman; J.D. Raese; R.G. Paulman; M.D. Devous Sr.; R.R. Gregory; A.J. Rush; H.H. Chehabi; F.J. Bonte), Brain Research Bulletin, Volume 85, 1984

“Dephosphorylation of Purified Brain Tyrosine Hydroxylase by Rat Striatal Extract”, (M.A. Lazar; J.D. Raese; J.D. Barchas), Neurochemistry International, Volume 5, pgs 107-111, 1983

“Genes for Catecholamine Biosynthesis: 1. Clone by Expression and Identification of the cDNA for Rat Dopamine- B- Hydroxylase”, (K.L. O’Malley; A. Mauron; J.D. Raese; J.D. Barchas; L. Kedes), Proc. National Academic of Science (USA), Volume 80, pgs 2161-2165, 1983

“Retinal Oscillatory Potentials in Schizophrenia: Implications for the Assessment of Dopamine Transmission in Man”, (J.D. Raese; R.J. King; P. Berger; J.D. Barchas), Psychopharmacology Bulletin, Volume 18, pgs 72-78, 1982

“Dopamine Neuronal Instability: A Model for the Schizophreniform Psychosis”, (R. King; J.D. Raese; B.A. Huberman; J.D. Barchas), Psychopharmacology Bulletin, Volume 18, pgs 69-72, 1982

“Thermal Denaturation of Native Striatal Tyrosine Hydroxylase: Increased Thermolability of the Phosphorylated Form of the Enzyme”, (M.A. Lazar; R.J.W. Truscott; J.D. Raese; and J.D. Barchas), Journal of Neurochemistry, Volume 36, pgs 677-682, 1981

“Tyrosine Hydroxylase from brain: Phosphorylation by Cyclic AMP- Dependent Protein Kinase”, (A.M. Edelman; J.D. Raese; J.D. Barchas), Journal of Pharmacology Experimental Therapy, Volume 216, pgs 647-653, 1981

“Regulatory Properties of Tyrosine Hydroxylase: Multiple Forms, Subunit Structure and Cyclic Nucleotide Independent- Phosphorylation“. In: Function and Regulatory of Monoamine Enzyme, Basic and Clinical Aspects”, (J.D. Raese; G. Makk; J.D. Barchas), Macmillan Publishers, Ltd., London, (eds.): E. Usdin, N. Weiner and M. Youdin, pgs105-114, 1981

“A Mathematical Model of Central Dopaminergic Transmission and the Dopamine Hypothesis of Schizophrenia”, (R. King; J.D. Raese; J.D. Barchas), In: Function and Regulatory of Monoamine Enzyme, Basic and Clinical Aspects Macmillan Publications, Ltd., London, (eds.): E. Usdin, N. Weiner and M. Youdin, pgs 399-406, 1981

“Further Studies on Neural Differentiation of the OTT-6050 Mouse Teratoma III: Enzymatic and Immunofluorescence Characterization of a Tumor Fraction Showing Melanogenesis in Neuroepithelial Cells”, (E. Erdelyi; S.R. Vandenberg; J.D. Raese; J.D. Barchas; L.J. Rubenstein; M. Herman), Virchows Archives (Pathological Anatomy), Volume 393, pgs 27-37, 1981

“Catastrophe Theory of Dopaminergic Transmission: A New Dopamine Hypothesis of Schizophrenia”, (R.J. King; J.D. Raese; J.D. Barchas), Journal of Theoretical Biology, Volume 92, pgs 373-400, 1981

“Phosphorylation of B- Lipotropin, B- Endorphin, Corticotrophin and Parathyroid Hormone: A Potential Control for Peptide Processing, In: Neural Peptides and Neuronal Communication”, (J.D. Raese; M.R. Boarder, G. Makk; J.D. Barchas), Raven Press, (eds.): E. Costa and M. Trabuchi, pgs 377-383, 1980

“Phosphorylation of Endogenous B- Lipotropin and Other Peptides by Slices Pituitary, Adult Brain and Neonate Brain of Rat“, In: “Endogenous and

Exogenous Opiate Agonists and Antagonists”, (M.R. Boarder; J.D. Raese; J. D. Barchas), Pergamon Press, New York, NY, (eds.): Way E.L., pgs 317-320, 1980

“B- Lipotropin, Corticotrophin and B- Endorphin: Phosphorylation by Cyclic AMP- Dependent and Independent Protein Kinesis“, In: “Endogenous Opiate Agonists and Antagonists”, (J. D. Raese; M.R. Boarder; G. Makk; J. D. Barchas), Pergamon Press, New York, NY, (eds.):Way E.L., pgs 317-320, 1980

“Tyrosine Hydroxylase from Brain: Phosphorylation of the Enzyme by Cyclic AMP- Dependent Protein Kinesis“, In “Catecholamines: Basic and Clinical Frontiers”, (J.D. Raese; A.M. Edelman; M.A. Lazar; J.D. Barchas), Pergamon Press, New York, NY/, London, (eds.): Kopin 1, E. Usdin and J.D. Barchas, Volume 1, pgs 46-48, 1979

“Brain Striatal Tyrosine Hydroxylase: Activation of the Enzyme of Cyclic AMP-Independent Phosphorylation”, (J. D. Raese; A.M. Edelman; G. Makk; E.A. Bruckwick; W. Lovenberg; J.D. Barchas), Communic. Psychopharmacology, Volume 3, pgs 295-301, 1979

“ In Vitro Phosphorylation of a Purified Preparation of Bovine Corpus Striatal Tyrosine Hydroxylase”, (A.M. Edelman; J.D. Raese; M.A. Lazar, J.D. Barchas), Communic Psychopharmacology, Volume 2, pgs 461-465, 1978

“Neuropharmacological Aspects of Affective Disorders”, In: “Depression: Clinical Biological and Psychological Perspectives”, (J.D. Barchas; R.L. Patrick; J.D. Raese; P. Berger), Brunner- Mazel, New York, NY, (eds.): E. Usdin, pgs 139-165, 1977

“Bovine Striatal Tyrosine Hydroxylase: Multiple Forms and Evidence for Phosphorylation by Cyclic AMP Dependent Protein Kinase”, In: “Structure and Function of Monoamine Enzymes”, (J.D. Raese; A.M. Edelman; M.A. Lazar; J.D. Barchas), Marcel Dekkar, New York, NY, (eds.): E. Usdin, N. Weiner, M.B.H. Youdin, pgs 383-400, 1977

“Sedative Hypnotics: Biological Mechanisms”, In: “Psychopharmacology for Theory to Practice”, (J.D. Raese), Oxford University Press, New York, NY, (eds.): J.D. Barchas; P.A. Berger, R.D. Ciaranello, G.R. Elliot, pgs 306-317, 1977

“Stimulation of Rat Striatal Tyrosine Hydroxylase by Phospholipid and Adenosine T, 5'- Monophosphate”, (J.D. Raese; R.L. Patrick; J.D. Barchas), Arzneim- Forsch (Drug Research), Volume 26, pgs 22-24, 1976

Phospholipid- Induced Activation of Tyrosine Hydroxylase from Rat Brain Striatal Synaptosome”, (J.D. Raese; R.L. Patrick; J.D. Barchas), Biochemical Pharmacology, Volume 25, pgs 2245-2250, 1976

“On the Origin of Homovanillic Acid in Urine“, (Uber Den Ursprung Der Homovanillin saure im Urin), (J.D. Raese; P. Schmiedek; E.J. Ehrlich), Arzneim- Forsch. (Drug Research), Volume 24, pgs 1088-1093, 1974

“Biochemical Mechanisms of Extrapyrmidal Motoric Side Effects of Haloperidol in Humans”, (Biochemische Mechanismen Der Extrapyrmidalmotorischen Wirkung von Haloperidol am Menschen),(E. Eben; M. Ackenheil; J.D. Raese; E. Ruether), Arzneim- Forsch, Volume 24, pgs 1133-1135, 1974

“Effect of Clozapine on MHPG, HVA and 5-HIAAS: Excretion in Urine and Cerebrospinal Fluid”, (Einfluss von Clozapine auf die MHPG-HVS- and 5-HIES-Ausscheidung in Urin and Liquor Cerebrospinalis), (M. Ackenheil; H. Beckman; G. Hoffman; E. Markianos, I Nystroem; J.D. Raese), Arzneim-Forsch. (Drug Research), Volume 24, pgs 984-987, 1974

“Autoradiographic Studies on the Influence of Gestagens on Estrogen- Induced Incorporation of 3H- Uridine and 3H- Thymidine into Nucleic Acids of the Rat Uterus”, (G. Trams; J.D. Raese; H. Maass), Gynecological Investigations, Volume 4, pgs 155-164, 1973

PRESENTATIONS

Effects of Mindfulness Meditation on Brain Networks,(Joachim Raese, invited speaker at the Kaweah Delta Culture in Psychiatry Conference, 2012)

Changes in Urinary Tyramine Sulfate Excretion Predict Treatment Response in Depression”, (J.L. Steinberg; M.H. Zielinski, P.J. Orsulak; L.B. Cates; J.D. Raese), Society of Biological Psychiatry Annual Meeting, New York, NY, 1990

“Wisconsin Card Sort Activated EEG Spectra in Schizophrenia”, (K.D. Pool; T. Finizto; K. Girisgen; J.L. Steinberg; J.D. Raese), Society of Biological Psychiatry Annual Meeting, New York, NY, 1990

“Differential Expression of Members of the Heat Shock Gene Family in Brain of Adult and Aged Rats”, (J.D. Raese; K. Groshan; S. Pardue; B. Border; E.K. Miller; M.R. Morrison- Bogorad), Second International Conference on Alzheimer’s Disease and Related Disorders, Toronto, Canada, 1990

“Human Dopamine Beta -Hydroxylase (DBH): In Vitro Transcription and Translation of Enzymatically Amplified cDNA”, (C.M. Craft; T.H. Thai; R.

Gonzales; J.D. Raese), Society of Neuroscience, Phoenix, AZ, 1989

“In- Situ Quantitation of Heat Shock 70 mRNAs in Rat Cerebellum After Amphetamine- Induced Hyperthermia”, (M.R. Morrison- Bogorad; K. Groshan; E.K. Miller; J.D. Raese), Society of Neuroscience, Phoenix, AZ, 1989

“The Family of Heat Shock Protein 70 mRNAs are Differentially Induced in Rat Cerebellum, Cortex and Non- Neuronal Tissues”, (E.K. Miller; J.D. Raese; M.R. Morrison- Bogorad), Society of Neuroscience, Phoenix, AZ, 1989

“1-123 Iodoamphetamine SPECT Imaging in Paranoid Schizophrenia”, (T.R. Simon; B.S. Walker; R.G. Paulman; S. Mattiesen; C.R. Judd; J.D. Raese), Society of Nuclear Medicine Meeting, San Francisco, CA, 1988

“Single- Proton Tomography Studies with Schizophrenia Patients”, (M.D. Devous Sr.; R.G. Paulman; S. Mattiesen; C. Judd; J.D. Raese), International Neuropsychological Society Meeting, Lahti, Finland, 1988

“Brain Electrical Activity Mapping in Paranoid Schizophrenia and Related Disorders”, (K.D. Pool; T. Finitzo; R.G. Paulman; C.R. Judd; R.R. Gregory; J.D. Raese), International Neuropsychological Society Meeting, Lahti, Finland, 1988

“SPECT Regional Cerebral Blood Flow Measurements Correlate with Neuropsychological Dysfunction in Schizophrenia Patients”, (M.D. Devous Sr.; R.G. Paulman; J.D. Raese; J.H. Herman; R.R. Gregory; F. J. Bonte), Society of Nuclear Medicine Meeting, Toronto, Canada, 1987

“Comparing Xenon 133 (Xe133) and 1-123 Iodoamphetamine (IMP) Single-Photon-Computed Tomography (SPECT) of the Brain in Schizophrenia”, (M.D. Devous, R.G. Paulman; J.D. Raese; J.H. Herman, R.R. Gregory; F. J. Bonte), Society of Biological Psychiatry Meeting, Chicago, IL, 1987

“The Differential Induction of Two HSP 70 mRNAs in Several Regions of Rat Brain by D- Amphetamine”,(E.K. Miller; M.D. Trulson; G.I. Mues; T.Z. Munn; M.L. Goggans; M.R. Morrison; J.D. Raese), Society of Neuroscience Meeting, New Orleans, LA, 1987

“Brain Electrical Activity Mapping in Paranoid Schizophrenia and Related Disorders”, (J.D. Raese, K.D. Pool; R.G. Paulman; T. Finitzo; C.R. Judd; R.R. Gregory; J. Steinberg), Society for Neuroscience Meeting, New Orleans, LA, 1987

“SPECT Determination of Regional Cerebral Blood Flow in Schizophrenia

During a Mental Task”, (M.D. Devous Sr.; J.D. Raese; J.H. Herman; R.G. Paulman; R.R. Gregory; A.J. Rush; H.H. Chehabi; F. J. Bonte), Society of Nuclear Medicine Meeting, West Palm Beach, FL, 1986

“EEG and Cerebral Blood Flow in Schizophrenic Patients”, (J.H. Herman, M.D. Devous Sr.; R.G. Paulman; P.L. Ramphy; F.J. Bonte; L.W. Chehabi; R.R. Gregory; H.P. Roffwarg; D. Raese), Society of Biological Psychiatry Meeting, Washington, DC, 1986

“SPECT rCBF Measurements Correlate with Neuropsychological Dysfunction in Schizophrenic Patients”, (M.D. Devous Sr.; R.G. Paulman; J.D. Raese; J.H. Herman; R.R. Gregory; F.J. Bonte), Society of Biological Psychiatry Meeting, Washington, DC, 1986

“SPECT Regional Cerebral Blood Flow Measurements Correlate with Neuropsychological Dysfunction in Schizophrenic Patients”, ((M.D. Devous Sr.; R.G. Paulman; J.D. Raese; J.H. Herman; R.R. Gregory; F.J. Bonte), Society of Nuclear Medicine Meeting, Washington, DC, 1986

“Complementary Single Photon Emission Computed Tomography of the Brain: Xeon and Iodoamphetamine”, (T.R. Simon; M.D. Devous Sr.; J.D. Raese; R. Homan; F.J. Bonte), Society of Nuclear Medicine Meeting, Washington, DC, 1986

“Personality Function in Temporal Lobe Epilepsy and Schizophrenia”, (R.G. Paulman; R.W. Homan; C. Segal; R.G. Gregory; J.D. Raese), American Psychological Association Meeting, Washington, DC, 1986

“Regional Cerebral Blood Flow in Schizophrenia”, (J.D. Raese; R.G. Paulman; M.D. Devous; R.R. Gregory; A.J. Rush; F.J. Bonte), American Psychiatric Association Meeting, Dallas, TX, 1985

“SPECT Determination of Regional Cerebral Blood Flow in Schizophrenic Patients at Rest and During a Mental Task”, (M.D. Devous Sr.; J.D. Raese; J.H. Herman; R.G. Paulman; R.R. Gregory; A.J. Rush; H.H. Chehabi; F.J. Bonte), Society of Nuclear Medicine Meeting, Houston, TX, 1985

“Neuropsychological Correlates of Structural and Metabolic Brain Dysfunction in Schizophrenia”, (R.G. Paulman; J.D. Raese; M.D. Devous Sr.; J.H. Herman; R.R. Gregory; H.H. Chehabi, F.J. Bonte), American Psychological Association Meeting, Los Angeles, CA, 1985

“Single- Photon Tomographic Determination of Regional Cerebral Blood Flow

JOACHIM RAESE, MD
CV PAGE 18

in Psychiatric Disorders”, (M.D. Devous Sr.; A.J. Rush; M.A. Schlessler, J. Debus; J.D. Raese; H.H. Chehabi, F.J. Bonte), Society of Nuclear Medicine, 31st Annual Meeting, Los Angeles, CA, 1984

“Neuropsychological Correlates of regional Cerebral Blood Flow in Schizophrenia”, (R.G. Paulman; M.D. Devous Sr.; F.J. Bonte; H.H. Chehabi; R.R. Gregory; A.J. Rush; J.D. Raese), National Association of Neuropsychologist Meeting, San Diego, CA, 1984

“Regional Blood Flow in Schizophrenia”, (J.D. Raese; R.R. Gregory; R.G. Paulman, A.J. Rush; M.D. Devous Sr.; H.H. Chehabi; F.J. Bonte), American Psychiatric Association, Annual Meeting, Los Angeles, CA, 1984

Signature

Date Signed